A	oplication No.	Applicant(s)	
	10/791,503	EVANS ET AL.	
	caminer	Art Unit	
44.	enjamin P. Blumel	1648	
The MAILING DATE of this communication appears All claims being allowable, PROSECUTION ON THE MERITS IS (OF herewith (or previously mailed), a Notice of Allowance (PTOL-85) or NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGH of the Office or upon petition by the applicant. See 37 CFR 1.313 an	R REMAINS) CLOSED in this apported in the communication TS. This application is subject to	plication. If not included will be mailed in due course.	THIS initiative
 This communication is responsive to <u>October 1, 2007</u>. 			
2. X The allowed claim(s) is/are 10-19,24-32,47,49-51,53,55-60 an	<u>d 62-68</u> .		
3.	en received. en received in Application No ents have been received in this his communication to file a reply T of this application. I. Note the attached EXAMINER eason(s) why the oath or declara e submitted. Is Patent Drawing Review (PTO- mendment / Comment or in the Comment or	national stage application from complying with the requirement S AMENDMENT or NOTICE of tion is deficient. 948) attached office action of	nts OF
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR 			
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 10/1/07	5. Notice of Informal P 6. Interview Summary Paper No./Mail Dat 7. Examiner's Amendr	(PTO-413), e	
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. ⊠ Examiner's Stateme	ent of Reasons for Allowance	

Art Unit: 1648

DETAILED ACTION

Applicants are informed that the rejections of the previous Office action not stated below have been withdrawn from consideration in view of the Applicant's arguments and/or amendments.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 1, 2007 has been entered.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on October 1, 2007 was filed after the mailing date of the Final Rejection on May 30, 2007. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Terminal Disclaimer

The terminal disclaimer filed on November 30, 2007 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of any patent granted on Application Number 11/071,095 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Application/Control Number: 10/791.503

Art Unit: 1648

Allowable Subject Matter

The following is an examiner's statement of reasons for allowance: The prior 103 (a) rejection maintained in the Final Rejection of May 30, 2007 has been withdrawn since no teachings in the prior art suggest the addition of EDTA/ethanol combination to a viral formulation. Furthermore, the specification states that adding this combination to adenovirus formulation reduces the loss of infectivity over time (see Examples 11-13 and figures 23, 27 and 28). Therefore, claims 10-19, 24-32, 47, 48-51, 53, 55-60 and 62-68 are allowable.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Summary

Claims 10-19, 24-32, 47, 48-51, 53, 55-60 and 62-68 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin P. Blumel whose telephone number is 571-272-4960. The examiner can normally be reached on M-F, 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-1600. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/791.503

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Benjamin P Blumel/ Examiner Art Unit 1648

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600